News
-
AstraZeneca has paid $7.25 million up-front with potential milestone payments of up to $225 million for a global licence from Synairgen for its SNG001 inhaled interferon beta for the treatment of viral respiratory tract infections… Read more . . .
-
OptiNose has announced three hires for senior management positions, which it says “will help drive the company forward in its mission to introduce new and valuable treatment options to the market utilizing its novel Bi-Directional… Read more . . .
-
Strativa Pharmaceuticals has announced that it has received FDA approval for its disposable single-dose device version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies. The new product… Read more . . .
-
CDMO Pharmaterials has announced that it will quadruple its GMP manufacturing capacity and add a dedicated inhalation development laboratory as part of an expansion of its Reading, UK site. The expansion plans also include additions… Read more . . .
-
Avanir Pharmaceuticals and OptiNose have announced that a Phase 3b trial demonstrated that acute migraine patients experienced greater pain relief within 30 minutes of dosing using Avanir’s AVP-825 intranasal sumatriptan powder than patients taking sumatriptan… Read more . . .
-
Aradigm has received a $5 million milestone payment from Grifols as the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis gets underway, the company announced.… Read more . . .
-
According to Smartinhaler manufacturer Nexus6, the FDA has granted 510(k) marketing clearance for a new version of the inhaler monitoring system called SmartTouch. The system includes a touch screen on the monitoring device and is… Read more . . .
-
Parion Sciences, which is developing a trans-nasal aerosol delivery system and several products for cystic fibrosis, has announced several changes to its executive team. Paul Boucher, previously VP of Finance & Business has been promoted… Read more . . .
-
Retrophin, which is developing Syntocinon intranasal oxytocin, has named Stephen Aselage as President and Chief Operations Officer and Alvin Shih as Executive VP of Research and Development. Aselage, who has stepped down as CEO, was… Read more . . .
-
Arikayce inhaled liposomal amikacin developer Insmed has announced that former AstraZeneca CEO David R. Brennan will join the company’s board of directors. Insmed Chairman of the Board Donald J. Hayden commented, “We are delighted to… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany